Logos Global Management LP Buys Forma Therapeutics Holdings Inc, Keros Therapeutics Inc, Global Blood Therapeutics Inc, Sells Reata Pharmaceuticals Inc, BioNTech SE, Arena Pharmaceuticals Inc

• New Purchases: FMTX, SRPT, DYN, RNA, ATHA, CMPS, SAGE, KYMR, HRMY, COGT, INBX, PMVP, OM, RLAY, NARI, AFIB,
• Added Positions: KROS, GBT, TGTX, BTAI, RPTX, CALT, LRMR,
• Reduced Positions: CLDX, PLRX, RAPT, KALV, AKUS, CYTK,
• Sold Out: RETA, BNTX, ARNA, AKBA, IMVT, ZGNX, PRNB, FULC, OBSV, IGMS, BLU, ETNB, APTO, SWTX, ISEE, RCKT, STRO, FUSN, XFOR, LUMO, MREO, APLT,

For the details of Logos Global Management LP's stock buys and sells, go to https://www.gurufocus.com/guru/logos+global+management+lp/current-portfolio/portfolio

1. Keros Therapeutics Inc (KROS) - 1,600,000 shares, 11.09% of the total portfolio. Shares added by 300.00%
2. Forma Therapeutics Holdings Inc (FMTX) - 1,173,188 shares, 10.51% of the total portfolio. New Position
3. Global Blood Therapeutics Inc (GBT) - 850,000 shares, 8.43% of the total portfolio. Shares added by 529.63%
4. TG Therapeutics Inc (TGTX) - 1,750,000 shares, 8.42% of the total portfolio. Shares added by 105.88%
5. Sarepta Therapeutics Inc (SRPT) - 275,000 shares, 6.94% of the total portfolio. New Position

Logos Global Management LP initiated holding in Forma Therapeutics Holdings Inc. The purchase prices were between $32.95 and $50.25, with an estimated average price of $40.52. The stock is now traded at around $38.32. The impact to a portfolio due to this purchase was 10.51%. The holding were 1,173,188 shares as of .

Logos Global Management LP initiated holding in Sarepta Therapeutics Inc. The purchase prices were between $127.12 and $172.34, with an estimated average price of $151.84. The stock is now traded at around $132.71. The impact to a portfolio due to this purchase was 6.94%. The holding were 275,000 shares as of .

Logos Global Management LP initiated holding in Dyne Therapeutics Inc. The purchase prices were between $20 and $23.9, with an estimated average price of $21.95. The stock is now traded at around $18.95. The impact to a portfolio due to this purchase was 5.82%. The holding were 1,604,392 shares as of .

Logos Global Management LP initiated holding in Avidity Biosciences Inc. The purchase prices were between $23.35 and $35.94, with an estimated average price of $28.87. The stock is now traded at around $28.40. The impact to a portfolio due to this purchase was 3.65%. The holding were 721,454 shares as of .

Logos Global Management LP initiated holding in Athira Pharma Inc. The purchase prices were between $16.02 and $18.46, with an estimated average price of $16.7. The stock is now traded at around $24.51. The impact to a portfolio due to this purchase was 3.39%. The holding were 1,020,812 shares as of .

Logos Global Management LP initiated holding in Compass Pathways PLC. The purchase prices were between $28.83 and $43.17, with an estimated average price of $35.95. The stock is now traded at around $34.29. The impact to a portfolio due to this purchase was 3.14%. The holding were 500,000 shares as of .

Logos Global Management LP added to a holding in Keros Therapeutics Inc by 300.00%. The purchase prices were between $27.04 and $62.21, with an estimated average price of $39.74. The stock is now traded at around $68.57. The impact to a portfolio due to this purchase was 8.32%. The holding were 1,600,000 shares as of .

Logos Global Management LP added to a holding in Global Blood Therapeutics Inc by 529.63%. The purchase prices were between $52.76 and $74.49, with an estimated average price of $63.55. The stock is now traded at around $42.62. The impact to a portfolio due to this purchase was 7.09%. The holding were 850,000 shares as of .

Logos Global Management LP added to a holding in TG Therapeutics Inc by 105.88%. The purchase prices were between $18.49 and $27.24, with an estimated average price of $22.98. The stock is now traded at around $29.98. The impact to a portfolio due to this purchase was 4.33%. The holding were 1,750,000 shares as of .

Logos Global Management LP added to a holding in BioXcel Therapeutics Inc by 83.33%. The purchase prices were between $37.44 and $64.63, with an estimated average price of $46.92. The stock is now traded at around $49.37. The impact to a portfolio due to this purchase was 1.95%. The holding were 550,000 shares as of .

Logos Global Management LP added to a holding in Repare Therapeutics Inc by 46.48%. The purchase prices were between $21.55 and $33.92, with an estimated average price of $26.53. The stock is now traded at around $27.79. The impact to a portfolio due to this purchase was 1.71%. The holding were 976,894 shares as of .

Logos Global Management LP added to a holding in Calliditas Therapeutics AB by 83.33%. The purchase prices were between $21.61 and $25.69, with an estimated average price of $23.27. The stock is now traded at around $32.76. The impact to a portfolio due to this purchase was 1.08%. The holding were 550,000 shares as of .

Logos Global Management LP sold out a holding in Reata Pharmaceuticals Inc. The sale prices were between $93.53 and $163.34, with an estimated average price of $125.03.

Logos Global Management LP sold out a holding in BioNTech SE. The sale prices were between $57.81 and $104.17, with an estimated average price of $71.42.

Logos Global Management LP sold out a holding in Arena Pharmaceuticals Inc. The sale prices were between $60.76 and $75.83, with an estimated average price of $66.59.

Logos Global Management LP sold out a holding in Akebia Therapeutics Inc. The sale prices were between $2.39 and $13.08, with an estimated average price of $8.75.

Logos Global Management LP sold out a holding in Immunovant Inc. The sale prices were between $22.61 and $38.9, with an estimated average price of $30.07.

Logos Global Management LP sold out a holding in Zogenix Inc. The sale prices were between $17.5 and $29.36, with an estimated average price of $24.56.